The metagenomic next-generation sequencing in diagnosing central nervous system angiostrongyliasis: a case report

BMC Infect Dis. 2020 Sep 21;20(1):691. doi: 10.1186/s12879-020-05410-y.

Abstract

Backgrounds: The incidence of angiostrongyliasis is increasing in recent decades due to the expanding endemic areas all over the world. Clinicians face tremendous challenge of diagnosing angiostrongyliasis because of the lack of awareness of the disease and less effective definitive laboratory tests.

Case presentation: A 27-year-old man initially manifested skin itching, emesis, myalgia and quadriparesis. With progressive weakness of four limbs and elevated protein in the cerebrospinal fluid (CSF), he was diagnosed as Guillain-Barré syndrome and treated with intravenous methylprednisolone and immunoglobulin. However, the patient deteriorated with hyperpyrexia, headache and then persistent coma. The routine tests for Angiostrongylus cantonensis (A. cantonensis) with both the CSF and the serum were all negative. In contrast, the metagenomic next-generation sequencing (mNGS) was applied with the serum sample and the CSF sample in the middle phase. The central nervous system (CNS) angiostrongyliasis was diagnosed by mNGS with the mid-phase CSF, but not the mid-phase serum. At the same time, the CSF analysis revealed eosinophils ratio up to 67%. The discovery of A. cantonensis was confirmed by PCR with CSF later. Unfortunately, the patient died of severe angiostrongyliasis. During his hospitalization, mNGS was carried out repeatedly after definitive diagnosis and targeted treatment. The DNA strictly map reads number of A. cantonensis detected by mNGS was positively correlated with the CSF opening pressure and clinical manifestations.

Conclusions: The case of A. cantonensis infection highlights the benefit of mNGS as a target-free identification in disclosing the rare CNS angiostrongyliasis in the unusual season, while solid evidence from routine clinical testing was absent. The appropriate sample of mNGS should be chosen according to the life cycle of A. cantonensis. Besides, given the fact that the DNA reads number of A. cantonensis fluctuated with CSF opening pressure and clinical manifestations, whether mNGS could be applied as a marker of effectiveness of treatment is worth further exploration.

Keywords: Angiostrongyliasis; Case report; Diagnosis; Eosinophilic meningoencephalitis; Metagenomic next-generation sequencing.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Albendazole / therapeutic use
  • Angiostrongylus cantonensis / genetics*
  • Animals
  • Anthelmintics / therapeutic use
  • Central Nervous System Helminthiasis / drug therapy
  • Central Nervous System Helminthiasis / etiology
  • Central Nervous System Helminthiasis / parasitology*
  • Cerebrospinal Fluid / parasitology
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Male
  • Metagenome
  • Methylprednisolone / therapeutic use
  • Polymerase Chain Reaction
  • Strongylida Infections / drug therapy
  • Strongylida Infections / etiology
  • Strongylida Infections / parasitology*

Substances

  • Anthelmintics
  • Albendazole
  • Methylprednisolone

Supplementary concepts

  • Angiostrongyliasis